Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.

Tessa StraatmijerVince B C BiemansDirk Jan A R MoesFrank HoentjenRob Ter HeineP W Jeroen MaljaarsRosaline TheeuwenMarieke PierikMarjolijn DuijvesteinAndrea E van der Meulen-de Jongnull null

Published in: Digestive diseases and sciences (2023)

In this real-world cohort of patients with CD, UST levels in the highest quartile (≥ 6.3 µg/mL) at week 8 were associated with higher biochemical remission rates at week 24.

Keyphrases

placebo controlled
disease activity
type diabetes
clinical trial
metabolic syndrome
rheumatoid arthritis
randomized controlled trial
ulcerative colitis
adipose tissue
double blind
insulin resistance